Login to Your Account



Financings roundup


Thursday, January 9, 2014
Lorus Therapeutics Inc., of Toronto, said underwriters have exercised in full their overallotment option to purchase an additional 1,909,500 common shares at a price of $0.55 per common share, in connection with their public offering.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription